abrocitinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
abrocitinib · Cibinqo
Marketed by Pfizer
NCT03349060 · Phase 3 · completed
A randomized, quadruple-blind, placebo-controlled phase 3 trial enrolling 387 participants with moderate-to-severe atopic dermatitis. The co-primary endpoints (IGA response and EASI-75 at week 12) were both statistically significant for the 100 mg and 200 mg doses versus placebo, with large absolute differences (e.g. 43.8% vs 7.9% for IGA). The adequate sample size, blinded design, and positive hard clinical endpoints justify the strong evidence grade.
Next expected readout: May 2027 · NCT07848074 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2; Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) (met)
Result source: NCT04345367
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)
Result source: NCT03607422
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | abrocitinib | upadacitinib |
|---|---|---|
| EASI-75 | 39.7% vs 11.8%+27.9 vs placeboNCT0334906094 other results
| 60.1% vs 13.3%+46.8 vs placeboNCT0360742263 other results
|
| IGA 0/1 with 2-point improvement | 27.8% vs 6.3%+21.5 vs placeboNCT0278016735 other results
| —Trial running · NCT03568318 |
| EASI-90 | 28.5% vs 14.6%vs DupilumabNCT0434536794 other results
| 42.4% vs 5.4%+37 vs placeboNCT0360742214 other results
|
| EASI, % change | -60% vs -28.6%−31.4 vs placeboNCT0357587151 other results
| -74.1% vs -34.5%−39.6 vs placeboNCT0360742269 other results
|
EASI-75
- abrocitinib
- 39.7% vs 11.8%+27.9 vs placeboNCT03349060
94 other results
- 44.5% vs 10.4% NCT03575871
- 58.7% vs 27.1% NCT03720470
- 68.5% vs 41.5% NCT03796676
- 62.7% vs 11.8% NCT03349060
- 61% vs 10.4% NCT03575871
- 70.3% vs 27.1% NCT03720470
- 72% vs 41.5% NCT03796676
- 46.5% vs 14% NCT03627767
- 54.2% vs 15.1% NCT03627767
- 60.4% vs 18% NCT03627767
- 60.3% vs 30.6% NCT03720470
- 76% vs 27% NCT03627767
- 100% vs 99.2% NCT03627767
- 38.3% vs 13.3% NCT03349060
- 43.3% vs 12.8% NCT03575871
- 55.6% vs 18.6% NCT03720470
- 60.4% vs 33.3% NCT03796676
- 27.6% vs 14.5% NCT03349060
- 26.5% vs 6.5% NCT03575871
- 44.6% vs 15.6% NCT03720470
- 41.3% vs 14.6% NCT03796676
- 10.3% vs 3.9% NCT03349060
- 10.2% vs 1.3% NCT03575871
- 25.4% vs 10.9% NCT03720470
- 19.6% vs 4.4% NCT03796676
- 65.8% vs 14% NCT03627767
- 71.8% vs 15.1% NCT03627767
- 80.5% vs 18% NCT03627767
- 71% vs 30.6% NCT03720470
- 92.5% vs 27% NCT03627767
- 99.6% vs 99.2% NCT03627767
- 57.8% vs 13.3% NCT03349060
- 60.4% vs 12.8% NCT03575871
- 67.9% vs 18.6% NCT03720470
- 68.5% vs 33.3% NCT03796676
- 47.4% vs 14.5% NCT03349060
- 51% vs 6.5% NCT03575871
- 57.4% vs 15.6% NCT03720470
- 63.8% vs 14.6% NCT03796676
- 24% vs 3.9% NCT03349060
- 24.3% vs 1.3% NCT03575871
- 30% vs 10.9% NCT03720470
- 25.5% vs 4.4% NCT03796676
- 73% vs 72.3% NCT04345367
- 76.1% vs 71.1% NCT04345367
- 77.3% vs 67.8% NCT04345367
- 76.3% vs 61.4% NCT04345367
- 71% vs 52.8% NCT04345367
- 57.6% vs 36.8% NCT04345367
- 29.4% vs 21.3% NCT04345367
- 25% vs 32.1% NCT02780167
- 35% vs 31.3% NCT02780167
- 36.8% vs 26.7% NCT02780167
- 40.7% vs 15.4% NCT02780167
- 40% vs 20% NCT02780167
- 38.2% vs 16.4% NCT02780167
- 27.3% vs 10.9% NCT02780167
- 12.7% vs 5.5% NCT02780167
- 3.6% vs 3.7% NCT02780167
- 36.8% vs 32.1% NCT02780167
- 45.5% vs 31.3% NCT02780167
- 55.6% vs 26.7% NCT02780167
- 64.6% vs 15.4% NCT02780167
- 73.6% vs 20% NCT02780167
- 68.5% vs 16.4% NCT02780167
- 57.4% vs 10.9% NCT02780167
- 36.5% vs 5.5% NCT02780167
- 16.7% vs 3.7% NCT02780167
- 3.7% vs 32.1% NCT02780167
- 6.9% vs 31.3% NCT02780167
- 12.9% vs 26.7% NCT02780167
- 13.3% vs 15.4% NCT02780167
- 22% vs 20% NCT02780167
- 18% vs 16.4% NCT02780167
- 20% vs 10.9% NCT02780167
- 6% vs 5.5% NCT02780167
- 6% vs 3.7% NCT02780167
- 38.5% vs 32.1% NCT02780167
- 25% vs 31.3% NCT02780167
- 27.6% vs 26.7% NCT02780167
- 17.4% vs 15.4% NCT02780167
- 22.4% vs 20% NCT02780167
- 18.4% vs 16.4% NCT02780167
- 18.4% vs 10.9% NCT02780167
- 12.2% vs 5.5% NCT02780167
- 2.1% vs 3.7% NCT02780167
- 43.8% vs 0% NCT03915496
- 46.7% vs 0% NCT03915496
- 46.7% vs 0% NCT03915496
- 6.3% vs 0% NCT03915496
- 78.6% vs 0% NCT03915496
- 78.6% vs 0% NCT03915496
- 50% vs 0% NCT03915496
- 38.5% vs 0% NCT03915496
- upadacitinib
- 60.1% vs 13.3%+46.8 vs placeboNCT03607422
63 other results
- 69.6% vs 16.3% NCT03569293
- 72.9% vs 13.3% NCT03607422
- 79.7% vs 16.3% NCT03569293
- 72.4% vs 62.6% NCT03738397
- 33% vs 3.6% NCT03607422
- 38.1% vs 3.6% NCT03569293
- 44% vs 3.6% NCT03607422
- 47.4% vs 3.6% NCT03569293
- 69% vs 13.3% NCT03607422
- 74.6% vs 12.1% NCT03569293
- 37.9% vs 6.7% NCT03607422
- 39.7% vs 3.4% NCT03569293
- 73.4% vs 13.3% NCT03607422
- 84.5% vs 12.1% NCT03569293
- 53.2% vs 6.7% NCT03607422
- 55.8% vs 3.4% NCT03569293
- 44.3% vs 18.2% NCT03738397
- 52.4% vs 9.8% NCT02925117
- 52.4% vs 7.3% NCT02925117
- 69% vs 9.8% NCT02925117
- 81% vs 7.3% NCT02925117
- 28.6% vs 9.8% NCT02925117
- 31% vs 7.3% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 80% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 85.7% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 20% vs 11.1% NCT02925117
- 25% vs 11.1% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 9.1% vs 11.1% NCT02925117
IGA 0/1 with 2-point improvement
- abrocitinib
- 27.8% vs 6.3%+21.5 vs placeboNCT02780167
35 other results
- 44.5% vs 6.3% NCT02780167
- 12.3% vs 6.3% NCT02780167
- 8.2% vs 6.3% NCT02780167
- 13.9% vs 10.7% NCT02780167
- 12.5% vs 18.8% NCT02780167
- 23.7% vs 10% NCT02780167
- 16.4% vs 5.5% NCT02780167
- 12.7% vs 14.5% NCT02780167
- 16.4% vs 1.8% NCT02780167
- 3.6% vs 3.6% NCT02780167
- 1.8% vs 0% NCT02780167
- 18.4% vs 10.7% NCT02780167
- 15.9% vs 18.8% NCT02780167
- 26.7% vs 10% NCT02780167
- 41.5% vs 5.5% NCT02780167
- 40.7% vs 14.5% NCT02780167
- 40.7% vs 1.8% NCT02780167
- 11.5% vs 3.6% NCT02780167
- 3.7% vs 0% NCT02780167
- 7.4% vs 10.7% NCT02780167
- 3.4% vs 18.8% NCT02780167
- 12.9% vs 10% NCT02780167
- 12% vs 5.5% NCT02780167
- 14% vs 14.5% NCT02780167
- 8% vs 1.8% NCT02780167
- 6% vs 3.6% NCT02780167
- 2% vs 0% NCT02780167
- 23.1% vs 10.7% NCT02780167
- 10.7% vs 18.8% NCT02780167
- 20.7% vs 10% NCT02780167
- 8.2% vs 5.5% NCT02780167
- 14.3% vs 14.5% NCT02780167
- 8.2% vs 1.8% NCT02780167
- 6.1% vs 3.6% NCT02780167
- 2.1% vs 0% NCT02780167
- upadacitinib
- —Trial running · NCT03568318
EASI-90
- abrocitinib
- 28.5% vs 14.6%vs DupilumabNCT04345367
94 other results
- 38% vs 11.3% NCT03720470
- 51.3% vs 13.9% NCT03627767
- 18.6% vs 5.3% NCT03349060
- 23.9% vs 3.9% NCT03575871
- 36.6% vs 10.1% NCT03720470
- 41.6% vs 18.1% NCT03796676
- 87.1% vs 84.6% NCT03627767
- 14.3% vs 5.3% NCT03349060
- 17.2% vs 2.6% NCT03575871
- 30.6% vs 7.8% NCT03720470
- 29.7% vs 14% NCT03796676
- 7.9% vs 3.9% NCT03349060
- 9.7% vs 0% NCT03575871
- 20.2% vs 6.3% NCT03720470
- 17.4% vs 2.1% NCT03796676
- 46.9% vs 10.5% NCT03627767
- 1.9% vs 1.3% NCT03349060
- 2.5% vs 0% NCT03575871
- 8.3% vs 2.3% NCT03720470
- 8.7% vs 0% NCT03796676
- 41.5% vs 12.1% NCT03627767
- 37.6% vs 10.6% NCT03627767
- 48.9% vs 11.3% NCT03720470
- 77.1% vs 13.9% NCT03627767
- 38.6% vs 5.3% NCT03349060
- 37.7% vs 3.9% NCT03575871
- 46.1% vs 10.1% NCT03720470
- 49.5% vs 18.1% NCT03796676
- 86.4% vs 84.6% NCT03627767
- 33.1% vs 5.3% NCT03349060
- 34.4% vs 2.6% NCT03575871
- 47.3% vs 7.8% NCT03720470
- 40.2% vs 14% NCT03796676
- 24.3% vs 3.9% NCT03349060
- 22.9% vs 0% NCT03575871
- 32.3% vs 6.3% NCT03720470
- 30.9% vs 2.1% NCT03796676
- 64.5% vs 10.5% NCT03627767
- 5.2% vs 1.3% NCT03349060
- 9.2% vs 0% NCT03575871
- 11.2% vs 2.3% NCT03720470
- 10.6% vs 0% NCT03796676
- 58.7% vs 12.1% NCT03627767
- 54.5% vs 10.6% NCT03627767
- 54.3% vs 41.9% NCT04345367
- 47.6% vs 33.6% NCT04345367
- 58.4% vs 45.7% NCT04345367
- 45.4% vs 25.4% NCT04345367
- 54.6% vs 47.6% NCT04345367
- 11.6% vs 7.2% NCT04345367
- 8.3% vs 14.3% NCT02780167
- 17.5% vs 15.6% NCT02780167
- 23.7% vs 10% NCT02780167
- 25.9% vs 9.6% NCT02780167
- 23.6% vs 5.5% NCT02780167
- 16.4% vs 7.3% NCT02780167
- 10.9% vs 1.8% NCT02780167
- 5.5% vs 0% NCT02780167
- 0% vs 0% NCT02780167
- 10.5% vs 14.3% NCT02780167
- 18.2% vs 15.6% NCT02780167
- 31.1% vs 10% NCT02780167
- 52.1% vs 9.6% NCT02780167
- 43.4% vs 5.5% NCT02780167
- 44.4% vs 7.3% NCT02780167
- 38.9% vs 1.8% NCT02780167
- 19.2% vs 0% NCT02780167
- 7.4% vs 0% NCT02780167
- 3.7% vs 14.3% NCT02780167
- 0% vs 15.6% NCT02780167
- 3.2% vs 10% NCT02780167
- 0% vs 9.6% NCT02780167
- 8% vs 5.5% NCT02780167
- 14% vs 7.3% NCT02780167
- 8% vs 1.8% NCT02780167
- 4% vs 0% NCT02780167
- 4% vs 0% NCT02780167
- 23.1% vs 14.3% NCT02780167
- 14.3% vs 15.6% NCT02780167
- 13.8% vs 10% NCT02780167
- 10.9% vs 9.6% NCT02780167
- 12.2% vs 5.5% NCT02780167
- 14.3% vs 7.3% NCT02780167
- 8.2% vs 1.8% NCT02780167
- 6.1% vs 0% NCT02780167
- 2.1% vs 0% NCT02780167
- 37.5% vs 0% NCT03915496
- 20% vs 0% NCT03915496
- 20% vs 0% NCT03915496
- 0% vs 0% NCT03915496
- 50% vs 0% NCT03915496
- 57.1% vs 0% NCT03915496
- 28.6% vs 0% NCT03915496
- 0% vs 0% NCT03915496
- upadacitinib
- 42.4% vs 5.4%+37 vs placeboNCT03607422
14 other results
- 53.1% vs 8.1% NCT03569293
- 58.5% vs 5.4% NCT03607422
- 65.8% vs 8.1% NCT03569293
- 48.3% vs 1.7% NCT03607422
- 47.6% vs 3.4% NCT03569293
- 62% vs 1.7% NCT03607422
- 74.1% vs 3.4% NCT03569293
- 61.6% vs 40.3% NCT03738397
- 26.2% vs 2.4% NCT02925117
- 26.2% vs 0% NCT02925117
- 50% vs 2.4% NCT02925117
- 45.2% vs 0% NCT02925117
- 14.3% vs 2.4% NCT02925117
- 9.5% vs 0% NCT02925117
EASI, % change
- abrocitinib
- -60% vs -28.6%−31.4 vs placeboNCT03575871
51 other results
- -77.3% vs -63.7% NCT03796676
- -59.5% vs -33% NCT03575871
- -72.6% vs -57.6% NCT03796676
- -54.3% vs -24.4% NCT03575871
- -66.1% vs -41.7% NCT03796676
- -39.2% vs -9% NCT03575871
- -51.5% vs -27.6% NCT03796676
- -73.3% vs -28.6% NCT03575871
- -80.6% vs -63.7% NCT03796676
- -73.2% vs -33% NCT03575871
- -77.8% vs -57.6% NCT03796676
- -69% vs -24.4% NCT03575871
- -74.3% vs -41.7% NCT03796676
- -51.3% vs -9% NCT03575871
- -54.5% vs -27.6% NCT03796676
- -27.7% vs -35.9% NCT02780167
- -38.8% vs -35.5% NCT02780167
- -51.2% vs -29.8% NCT02780167
- -59.0% vs -35.2% NCT02780167
- -54.0% vs -36.7% NCT02780167
- -54.2% vs -39.2% NCT02780167
- -53.6% vs -24.6% NCT02780167
- -38.3% vs -23.5% NCT02780167
- -19.9% vs -12.3% NCT02780167
- -55.8% vs -35.9% NCT02780167
- -57.1% vs -35.5% NCT02780167
- -66.3% vs -29.8% NCT02780167
- -82.6% vs -35.2% NCT02780167
- -84.5% vs -36.7% NCT02780167
- -83.1% vs -39.2% NCT02780167
- -78.2% vs -24.6% NCT02780167
- -63.3% vs -23.5% NCT02780167
- -41.3% vs -12.3% NCT02780167
- -20.8% vs -35.9% NCT02780167
- -26.3% vs -35.5% NCT02780167
- -33.0% vs -29.8% NCT02780167
- -40.7% vs -35.2% NCT02780167
- -36.8% vs -36.7% NCT02780167
- -40.2% vs -39.2% NCT02780167
- -32.8% vs -24.6% NCT02780167
- -26.3% vs -23.5% NCT02780167
- -14.8% vs -12.3% NCT02780167
- -45.2% vs -35.9% NCT02780167
- -31.5% vs -35.5% NCT02780167
- -34.1% vs -29.8% NCT02780167
- -31.1% vs -35.2% NCT02780167
- -39.4% vs -36.7% NCT02780167
- -35.2% vs -39.2% NCT02780167
- -30.1% vs -24.6% NCT02780167
- -14.8% vs -23.5% NCT02780167
- -13.8% vs -12.3% NCT02780167
- upadacitinib
- -74.1% vs -34.5%−39.6 vs placeboNCT03607422
69 other results
- -80.2% vs -40.7% NCT03569293
- -84.7% vs -34.5% NCT03607422
- -87.7% vs -40.7% NCT03569293
- -77.8% vs -42.2% NCT03607422
- -82.1% vs -43.5% NCT03569293
- -84.8% vs -42.2% NCT03607422
- -89.4% vs -43.5% NCT03569293
- -61.7% vs -23% NCT02925117
- -74.4% vs -23% NCT02925117
- -39.4% vs -23% NCT02925117
- 582.3% vs 50.7% NCT02925117
- 65.7% vs 50.7% NCT02925117
- -65.4% vs -17.5% NCT02925117
- 607.3% vs 13.5% NCT02925117
- 72.6% vs 13.5% NCT02925117
- 613.3% vs -2.3% NCT02925117
- 151.7% vs -2.3% NCT02925117
- 608.8% vs -31.2% NCT02925117
- 154.1% vs -31.2% NCT02925117
- 613.8% vs -29.8% NCT02925117
- 104.1% vs -29.8% NCT02925117
- 614.6% vs -35.8% NCT02925117
- 104.1% vs -35.8% NCT02925117
- 614% vs -37.3% NCT02925117
- 130.2% vs -37.3% NCT02925117
- 617.5% vs -37.7% NCT02925117
- 99.3% vs -37.7% NCT02925117
- -73.8% vs 50.7% NCT02925117
- -82.8% vs -17.5% NCT02925117
- -67.5% vs 13.5% NCT02925117
- 898.5% vs 13.5% NCT02925117
- -69.6% vs 13.5% NCT02925117
- -83.1% vs -2.3% NCT02925117
- 771.5% vs -2.3% NCT02925117
- -28.8% vs -2.3% NCT02925117
- -92% vs -31.2% NCT02925117
- 778.9% vs -31.2% NCT02925117
- 140.6% vs -31.2% NCT02925117
- -90.1% vs -29.8% NCT02925117
- 799.5% vs -29.8% NCT02925117
- -13.3% vs -29.8% NCT02925117
- -91.4% vs -35.8% NCT02925117
- 802.1% vs -35.8% NCT02925117
- 63.6% vs -35.8% NCT02925117
- -90.3% vs -37.3% NCT02925117
- 787.8% vs -37.3% NCT02925117
- 24.4% vs -37.3% NCT02925117
- -84.6% vs -37.7% NCT02925117
- 769.7% vs -37.7% NCT02925117
- 39% vs -37.7% NCT02925117
- 186% vs 50.7% NCT02925117
- 79.1% vs 50.7% NCT02925117
- -43.7% vs -17.5% NCT02925117
- 11.8% vs 50.7% NCT02925117
- 791.5% vs 50.7% NCT02925117
- 189.6% vs 13.5% NCT02925117
- 59% vs 13.5% NCT02925117
- 181.5% vs -2.3% NCT02925117
- 63.5% vs -2.3% NCT02925117
- 200.9% vs -31.2% NCT02925117
- 77.6% vs -31.2% NCT02925117
- 189.1% vs -29.8% NCT02925117
- 74.4% vs -29.8% NCT02925117
- 179.9% vs -35.8% NCT02925117
- 71.8% vs -35.8% NCT02925117
- 201.4% vs -37.3% NCT02925117
- 77.7% vs -37.3% NCT02925117
- 170.7% vs -37.7% NCT02925117
- 69.1% vs -37.7% NCT02925117
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. abrocitinib: 15 of 15 rows · upadacitinib: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | abrocitinib Rows use multiple source trials | upadacitinib Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points | -80.6% (n=362) vs -73.7% (n=365) Dupilumab @ 16wk200 mg QDa,b,c NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8 other source trials-32.9% (n=238) vs -19.6% (n=131) placebo @ 16wk100 mg NCT03720470 · Phase 3 -39% (n=226) vs -19.6% (n=131) placebo @ 16wk200 mg NCT03720470 · Phase 3 -90.9% (n=264) vs -68.5% (n=266) placebo @ 16wk100 mg NCT03627767 · Phase 3 · registry result, not featured evidence -96.3% (n=265) vs -68.5% (n=266) placebo @ 16wk200 mg NCT03627767 · Phase 3 · registry result, not featured evidence -5.55% (n=56) vs -8.09% (n=56) placebo @ 16wk100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -14.64% (n=49) vs -8.09% (n=56) placebo @ 16wk10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -17.88% (n=55) vs -8.09% (n=56) placebo @ 16wk200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -3.52% (n=51) vs -8.09% (n=56) placebo @ 16wk30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence | -27.1% (n=42) vs -4.1% (n=39) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses-30.7% (n=42) vs -4.1% (n=39) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence -11.7% (n=42) vs -4.1% (n=39) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| DLQI 4-point Improvement responder rate · % of participants | 67.2% (n=117) vs 43.6% (n=56) placebo @ 12wk100 mgd,b,c,e NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose72.6% (n=117) vs 43.6% (n=56) placebo @ 12wk200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 68.2% (n=22) vs 19.2% (n=26) placebo @ 16wk15 mg QDd,b,c,e NCT03607422 · Phase 3 show 3 more doses71.7% (n=251) vs 28.4% (n=250) placebo @ 16wk15 mg QD NCT03607422 · Phase 3 73.3% (n=30) vs 19.2% (n=26) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 77.6% (n=251) vs 28.4% (n=250) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 |
| EASI 100 responder rate · % of participants | 12.7% (n=238) vs 4% (n=131) placebo @ 16wk100 mgd,b,c NCT03720470 · Phase 3 show 1 more dose13.6% (n=226) vs 4% (n=131) placebo @ 16wk200 mg NCT03720470 · Phase 3 | 15.5% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QDd,b,c NCT03607422 · Phase 3 show 3 more doses14.1% (n=276) vs 0.7% (n=278) placebo @ 16wk15 mg QD NCT03607422 · Phase 3 19.4% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 18.8% (n=282) vs 0.7% (n=278) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 |
| EASI-50 responder rate · % of participants | 81.2% (n=238) vs 57.3% (n=131) placebo @ 16wk100 mgd,a,b,c NCT03720470 · Phase 3 show 1 more dose87.3% (n=226) vs 57.3% (n=131) placebo @ 16wk200 mg NCT03720470 · Phase 3 | 71.4% (n=42) vs 22% (n=41) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses83.3% (n=42) vs 22% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 50% (n=42) vs 22% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| EASI-75 responder rate · % of participants No placebo or comparator arm | 69% (n=100) @ 12wk100 mgd,f,b,c NCT05375929 · Phase 3 · registry result, not featured evidence show 1 more dose71.7% (n=99) @ 12wk200 mg NCT05375929 · Phase 3 · registry result, not featured evidence | 64.4% (n=222) @ 12wk15 mgd,f,b,c NCT05507580 · Phase 4 · registry result, not featured evidence show 1 more dose79.3% (n=227) @ 12wk30 mg NCT05507580 · Phase 4 · registry result, not featured evidence |
| IGA 0/1 responder rate · % of participants | 55.3% (n=362) vs 42.5% (n=365) Dupilumab @ 16wk200 mg QDa,b,c NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 other source trials55.5% (n=264) vs 15.4% (n=267) placebo @ 16wk100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 77.8% (n=266) vs 15.4% (n=267) placebo @ 16wk200 mg NCT03627767 · Phase 3 · registry result, not featured evidence | 31% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Pruritus NRS 4-point Improvement responder rate · % of participants | 54.6% (n=254) vs 15.9% (n=258) placebo @ 16wk100 mgd,a,b,c NCT03627767 · Phase 3 · registry result, not featured evidence show 1 more dose75.6% (n=250) vs 15.9% (n=258) placebo @ 16wk200 mg NCT03627767 · Phase 3 · registry result, not featured evidence | 59.4% (n=32) vs 5.7% (n=35) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses52.8% (n=36) vs 5.7% (n=35) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 24.3% (n=37) vs 5.7% (n=35) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| SCORAD percent change · % of baseline | -70.6% (n=362) vs -64.4% (n=365) Dupilumab @ 16wk200 mg QDb,c NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 6 other source trials-71.7% (n=264) vs -50.4% (n=265) placebo @ 16wk100 mg NCT03627767 · Phase 3 · registry result, not featured evidence -83.6% (n=265) vs -50.4% (n=265) placebo @ 16wk200 mg NCT03627767 · Phase 3 · registry result, not featured evidence -29.13% (n=56) vs -31.972% (n=56) placebo @ 16wk100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -30.135% (n=49) vs -31.972% (n=56) placebo @ 16wk10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -34.995% (n=55) vs -31.972% (n=56) placebo @ 16wk200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence -19.794% (n=51) vs -31.972% (n=56) placebo @ 16wk30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence | -57.89% (n=54) vs -27.91% (n=30) placebo @ 16wk15 mg QDd,b,c NCT03607422 · Phase 3 show 3 more doses-57.9% (n=245) vs -28.43% (n=136) placebo @ 16wk15 mg QD NCT03607422 · Phase 3 -72.81% (n=49) vs -27.91% (n=30) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 -68.44% (n=241) vs -28.43% (n=136) placebo @ 16wk30 mg QD NCT03607422 · Phase 3 |
| SCORAD 50 responder rate · % of participants | 56.1% (n=238) vs 33.3% (n=131) placebo @ 16wk100 mgd,a,b,c NCT03720470 · Phase 3 show 1 more dose68.8% (n=226) vs 33.3% (n=131) placebo @ 16wk200 mg NCT03720470 · Phase 3 | 42.9% (n=42) vs 7.3% (n=41) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses61.9% (n=42) vs 7.3% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 28.6% (n=42) vs 7.3% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| SCORAD75 responder rate · % of participants | 26.8% (n=238) vs 10.6% (n=131) placebo @ 16wk100 mgd,a,b,c NCT03720470 · Phase 3 show 1 more dose40.3% (n=226) vs 10.6% (n=131) placebo @ 16wk200 mg NCT03720470 · Phase 3 | 21.4% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mgd,a,b,c NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses40.5% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Time to Loss of Response time to event · months | 2.56 vs 0.89 placebo months*100 mgd,a,b,c,g NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 78 days as posted show 3 more doses10.61 vs 0.92 placebo months*100 mg NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 323 days as posted 6.6 vs 0.89 placebo months*200 mg NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 201 days as posted NA vs 0.92 placebo months200 mg NCT03627767 · Phase 3 · registry result, not featured evidence | 0.99 vs NA placebo months*15 mgd,a,b,c,g NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 30 days as posted show 6 more doses3.75 vs NA placebo months*15 mg NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 114 days as posted NA vs NA placebo months30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0.92 vs NA placebo months*30 mg NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted NA vs NA placebo months30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0.95 vs NA placebo months*7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 29 days as posted NA vs NA placebo months7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 13.5%100 mgh NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results11%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 9.7%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 13.3%100 mg NCT03575871 · Phase 3 9%200 mg NCT03575871 · Phase 3 —100 mg NCT03720470 · Phase 3 8.8%100 mg NCT03720470 · Phase 3 —200 mg NCT03720470 · Phase 3 8%200 mg NCT03720470 · Phase 3 3.2%100mg QD NCT03796676 · Phase 3 3.2%200mg QD NCT03796676 · Phase 3 6.9%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 8.1%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —200 mg NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 35.4%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 12.5%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 7.1%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 33.9%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 30.9%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 47.1%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 44.9%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence | —15 mgi NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 5.2%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 4.1%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 3.2%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 4.5%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 3.3%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 4.9%30 mg QD NCT03569293 · Phase 3 5.2%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 2.6%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 10.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 16.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 8.8%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 11.9%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 26.2%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 5.8%100 mgh NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results5.8%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%100 mg NCT03575871 · Phase 3 3.2%200 mg NCT03575871 · Phase 3 —100 mg NCT03720470 · Phase 3 2.5%100 mg NCT03720470 · Phase 3 —200 mg NCT03720470 · Phase 3 4%200 mg NCT03720470 · Phase 3 1.1%100mg QD NCT03796676 · Phase 3 2.1%200mg QD NCT03796676 · Phase 3 0%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 1%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —200 mg NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 4%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 12.5%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 7.1%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 21.4%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 14.5%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 15.7%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 16.3%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence | —15 mgi NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0.4%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 0.4%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 1.6%30 mg QD NCT03569293 · Phase 3 —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 2%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.2%100 mgh NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results3.2%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.7%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%100 mg NCT03575871 · Phase 3 1.3%200 mg NCT03575871 · Phase 3 2.5%100 mg NCT03720470 · Phase 3 0.5%100 mg NCT03720470 · Phase 3 0.9%200 mg NCT03720470 · Phase 3 0%200 mg NCT03720470 · Phase 3 0%100mg QD NCT03796676 · Phase 3 1.1%200mg QD NCT03796676 · Phase 3 1%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 0%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence 0%200 mg NCT05375929 · Phase 3 · registry result, not featured evidence 3.4%100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 1.6%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 5.3%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 1.1%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 0%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 0%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 5.4%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 3.6%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 0%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 4.1%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence | 15.4%15 mgi NCT03607422 · Phase 3 show 48 more results10.9%15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 10.6%15 mg NCT03607422 · Phase 3 16.6%15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 13.8%30 mg NCT03607422 · Phase 3 16.9%30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 17.3%30 mg NCT03607422 · Phase 3 17.4%30 mg NCT03607422 · Phase 3 2.8%30 mg QD NCT03607422 · Phase 3 3.3%15 mg NCT03569293 · Phase 3 12.5%15 mg QD NCT03569293 · Phase 3 3.1%15 mg QD NCT03569293 · Phase 3 14.7%15 mg NCT03569293 · Phase 3 14.3%15 mg NCT03569293 · Phase 3 2.1%15 mg QD NCT03569293 · Phase 3 22.2%30 mg NCT03569293 · Phase 3 10.9%30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 20%30 mg NCT03569293 · Phase 3 18.4%30 mg NCT03569293 · Phase 3 3.3%30 mg QD NCT03569293 · Phase 3 3.5%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.4%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.7%15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.8%30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 5.9%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 5.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.1%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 6.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mgh nasopharyngitis 14.7% (placebo 10.4%) dermatitis atopic 14.1% (placebo 16.9%) nausea 9% (placebo 2.6%) NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results200 mg nausea 20.1% (placebo 2.6%) nasopharyngitis 11.7% (placebo 10.4%) headache 9.7% (placebo 2.6%) NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 200 mg QD nausea 19.3% headache 13% acne 12.7% NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 100 mg nasopharyngitis 12.7% (placebo 6.4%) upper respiratory tract infection 8.9% (placebo 3.8%) nausea 7.6% (placebo 2.6%) NCT03575871 · Phase 3 200 mg nausea 14.2% (placebo 2.6%) headache 7.7% (placebo 2.6%) nasopharyngitis 7.7% (placebo 6.4%) NCT03575871 · Phase 3 100 mg nasopharyngitis 9.2% (placebo 6.9%) upper respiratory tract infection 5% (placebo 4.6%) headache 4.2% (placebo 4.6%) NCT03720470 · Phase 3 100 mg upper respiratory tract infection 2.8% (placebo 4.6%) cough 1.4% (placebo 1.5%) diarrhoea 1.4% (placebo 3.1%) NCT03720470 · Phase 3 200 mg nausea 11.1% (placebo 1.5%) acne 6.6% (placebo 0%) headache 6.6% (placebo 4.6%) NCT03720470 · Phase 3 200 mg nasopharyngitis 4.3% (placebo 6.9%) upper respiratory tract infection 2.4% (placebo 4.6%) dermatitis atopic 1.9% (placebo 3.1%) NCT03720470 · Phase 3 100mg QD upper respiratory tract infection 9.5% (placebo 10.4%) nasopharyngitis 8.4% (placebo 9.4%) folliculitis 7.4% (placebo 1%) NCT03796676 · Phase 3 200mg QD nausea 18.1% (placebo 1%) upper respiratory tract infection 10.6% (placebo 10.4%) headache 8.5% (placebo 7.3%) NCT03796676 · Phase 3 100 mg QD nausea 5% dermatitis atopic 4% alanine aminotransferase increased 3% NCT05375929 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10.5% nausea 10.5% cough 5.3% NCT05375929 · Phase 3 · registry result, not featured evidence 200 mg QD nausea 9.1% gastrooesophageal reflux disease 4% pruritus 4% NCT05375929 · Phase 3 · registry result, not featured evidence 200 mg dermatitis atopic 12.5% pyrexia 12.5% asthma 6.3% NCT05375929 · Phase 3 · registry result, not featured evidence 100 mg dermatitis atopic 21.1% (placebo 33%) nausea 13.2% (placebo 16.5%) nasopharyngitis 10.2% (placebo 9.7%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg nausea 16.1% (placebo 16.5%) headache 9.7% (placebo 11.6%) nasopharyngitis 6.2% (placebo 9.7%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg nausea 18.4% (placebo 16.5%) dermatitis atopic 13.5% (placebo 33%) acne 11.7% (placebo 7.1%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg upper respiratory tract infection 6% (placebo 9.7%) nasopharyngitis 4.8% (placebo 9.7%) dermatitis atopic 3.7% (placebo 33%) NCT03627767 · Phase 3 · registry result, not featured evidence 100 mg QD nausea 18.8% (placebo 6.3%) dizziness 12.5% (placebo 0%) abdominal discomfort 6.3% (placebo 0%) NCT03915496 · Phase 2 · registry result, not featured evidence 200 mg QD nausea 28.6% (placebo 6.3%) headache 14.3% (placebo 0%) abdominal distension 7.1% (placebo 0%) NCT03915496 · Phase 2 · registry result, not featured evidence 100mg QD viral upper respiratory tract infection 17.9% (placebo 8.9%) dermatitis atopic 12.5% (placebo 10.7%) headache 8.9% (placebo 3.6%) NCT02780167 · Phase 2 · registry result, not featured evidence 200mg QD nausea 14.5% (placebo 1.8%) dermatitis atopic 12.7% (placebo 10.7%) viral upper respiratory tract infection 12.7% (placebo 8.9%) NCT02780167 · Phase 2 · registry result, not featured evidence 30mg QD dermatitis atopic 17.6% (placebo 10.7%) viral upper respiratory tract infection 11.8% (placebo 8.9%) headache 9.8% (placebo 3.6%) NCT02780167 · Phase 2 · registry result, not featured evidence 10mg QD dermatitis atopic 16.3% (placebo 10.7%) viral upper respiratory tract infection 10.2% (placebo 8.9%) diarrhoea 6.1% (placebo 1.8%) NCT02780167 · Phase 2 · registry result, not featured evidence | 15 mgi covid-19 23.1% (placebo 0%) acne 19.2% (placebo 3.3%) dermatitis atopic 19.2% (placebo 13.3%) NCT03607422 · Phase 3 show 38 more results15 mg covid-19 27.3% (placebo 0%) upper respiratory tract infection 21.8% (placebo 1.7%) acne 18.2% (placebo 3.3%) NCT03607422 · Phase 3 15 mg QD acne 10.3% (placebo 3.3%) upper respiratory tract infection 10.3% (placebo 1.7%) oropharyngeal pain 6.9% (placebo 0%) NCT03607422 · Phase 3 15 mg covid-19 31.7% (placebo 0%) acne 19.2% (placebo 3.3%) blood creatine phosphokinase increased 17.3% (placebo 1.7%) NCT03607422 · Phase 3 15 mg covid-19 31.9% (placebo 0%) dermatitis atopic 17.9% (placebo 13.3%) upper respiratory tract infection 14.4% (placebo 1.7%) NCT03607422 · Phase 3 15 mg QD acne 12.8% (placebo 3.3%) headache 7% (placebo 3.3%) nasopharyngitis 6.2% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 41.4% (placebo 0%) acne 34.5% (placebo 3.3%) dermatitis atopic 24.1% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 32.2% (placebo 0%) blood creatine phosphokinase increased 18.6% (placebo 1.7%) acne 11.9% (placebo 3.3%) NCT03607422 · Phase 3 30 mg QD acne 14.5% (placebo 3.3%) blood creatine phosphokinase increased 9.7% (placebo 1.7%) headache 8.1% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 39.4% (placebo 0%) acne 25% (placebo 3.3%) dermatitis atopic 15.4% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 29.8% (placebo 0%) blood creatine phosphokinase increased 18.3% (placebo 1.7%) dermatitis atopic 14.9% (placebo 13.3%) NCT03607422 · Phase 3 30 mg QD acne 15% (placebo 3.3%) nasopharyngitis 8.1% (placebo 3.3%) headache 6.5% (placebo 3.3%) NCT03607422 · Phase 3 15 mg covid-19 20% (placebo 0%) acne 16.7% (placebo 1.6%) blood creatine phosphokinase increased 16.7% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD covid-19 25% (placebo 0%) upper respiratory tract infection 21.9% (placebo 8.2%) blood creatine phosphokinase increased 12.5% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD acne 14.1% (placebo 1.6%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) headache 7.8% (placebo 3.3%) NCT03569293 · Phase 3 15 mg covid-19 38.2% (placebo 0%) dermatitis atopic 18.6% (placebo 3.3%) upper respiratory tract infection 18.6% (placebo 8.2%) NCT03569293 · Phase 3 15 mg covid-19 28.6% (placebo 0%) nasopharyngitis 16.5% (placebo 1.6%) dermatitis atopic 16% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD upper respiratory tract infection 9.6% (placebo 8.2%) nasopharyngitis 7.9% (placebo 1.6%) acne 5.4% (placebo 1.6%) NCT03569293 · Phase 3 30 mg acne 37% (placebo 1.6%) upper respiratory tract infection 33.3% (placebo 8.2%) dermatitis atopic 29.6% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD covid-19 35.9% (placebo 0%) acne 28.1% (placebo 1.6%) upper respiratory tract infection 28.1% (placebo 8.2%) NCT03569293 · Phase 3 30 mg QD acne 15.6% (placebo 1.6%) upper respiratory tract infection 12.5% (placebo 8.2%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 38.1% (placebo 0%) acne 22.9% (placebo 1.6%) blood creatine phosphokinase increased 17.1% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 35.1% (placebo 0%) acne 18.9% (placebo 1.6%) dermatitis atopic 18% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD acne 16.5% (placebo 1.6%) upper respiratory tract infection 12.8% (placebo 8.2%) nasopharyngitis 11.5% (placebo 1.6%) NCT03569293 · Phase 3 15 mg acne 7% nasopharyngitis 5.7% upper respiratory tract infection 3.5% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg nasopharyngitis 11.1% dermatitis atopic 8.3% upper respiratory tract infection 6.9% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg then 30 mg dermatitis atopic 16% nasopharyngitis 4.2% acne 2.8% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 13.8% nasopharyngitis 9.1% dermatitis atopic 3.9% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg then 15 mg dermatitis atopic 12% nasopharyngitis 7.5% acne 6% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg dermatitis atopic 16.5% acne 6.6% eczema 5.5% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 20.5% covid-19 13.4% blood creatine phosphokinase increased 13% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg acne 22.9% dermatitis atopic 19.1% blood creatine phosphokinase increased 14.8% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg QD acne 18.7% dermatitis atopic 10.5% blood creatine phosphokinase increased 7.6% NCT03738397 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) nasopharyngitis 11.9% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 11.9% (placebo 5.4%) nasopharyngitis 9.5% (placebo 1.1%) blood creatine phosphokinase increased 7.1% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 22.8% (placebo 5.4%) dermatitis atopic 19.3% (placebo 2.2%) acne 11.4% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg acne 14.3% (placebo 1.1%) upper respiratory tract infection 11.9% (placebo 5.4%) blood creatine phosphokinase increased 9.5% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 14.3% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 16 weeks versus 12 weeks.
- fTrial phases differ: Phase 4 versus Phase 3.
- gThe assessment timepoint is not available for both results.
- hPopulation comparability has not been reviewed for 22 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
abrocitinib
show 55 more results
show 2 more results
show 15 more results
show 7 more results
show 17 more results
show 23 more results
show 51 more results
show 7 more results
show 60 more results
show 25 more results
show 7 more results
show 7 more results
+ 115 further endpoints in the CSV export.
upadacitinib
show 7 more results
show 38 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: abrocitinib's landscape · upadacitinib's landscape